Cardinal Health, Inc. (CAH) Up 6.7% — Buy the Breakout?
Cardinal Health, Inc. (CAH) is surging on Thursday, last trading at $279.45 on the NYSE. That is a $17.52 gain from the prior close of $261.93 and pushes the stock into record territory for the year. The move clears the previous 52-week high of $259.84, set just last week on October 30, 2026, and the shares now trade roughly 7.5% above that level. Measured against the 52-week low of $180.45, CAH has climbed nearly 55%, a run that today's session extends with authority.
With the regular session still underway, about 563,229 shares have traded so far against a 90-day average of roughly 1.89 million. That puts intraday turnover at about 30% of a typical full day's volume.
Why Cardinal Health, Inc. Price is Moving Higher
The driver is a clean earnings beat paired with raised guidance. Cardinal Health reported fiscal Q1 2027 adjusted EPS of $3.26 on November 5 against the Zacks consensus of $2.92. That is a $0.34 beat and a 28% jump from $2.55 a year earlier. Revenue reached $67.51 billion, up 5.5% from $64.01 billion in the prior-year quarter and about 0.83% ahead of the roughly $66.95 billion consensus. On a GAAP basis, EPS rose 27% to $2.38, and net income attributable to Cardinal climbed 23% to $554 million. Profit grew several times faster than the top line, which is the kind of operating leverage investors reward in a high-volume, thin-margin business.
The forward-looking piece did the heavy lifting. Management lifted full-year adjusted EPS guidance to $12.80–$13.00, up from $12.40–$12.60. The new range sits above the $12.55 Zacks estimate midpoint. The engine behind the raise is the Pharmaceutical and Specialty Solutions segment, where revenue rose 6% to $62.6 billion and segment profit grew 17% to $783 million on strength in brand and specialty drug sales and solid generics performance. Cardinal also raised that segment's profit-growth outlook to 10%–12% from 8%–11%. That signals management sees the momentum carrying through the rest of the fiscal year.
The broader peer group added support. McKesson Corporation (MCK) is up 3.16% today, which points to positive read-through across drug distribution. Cardinal's own beat-and-raise remains the clear company-specific catalyst, and it explains why CAH is outrunning its closest peer by a wide margin.
What is the Cardinal Health, Inc. Rating - Should I Buy?
Weiss Ratings assigns CAH a B+ rating. The rating was downgraded on 10/13/2026. Current recommendation is Buy. The October adjustment trimmed the rating without changing the recommendation. Today's results, which include a raised outlook and accelerating segment profit, reinforce the case for a stock that already sits near the top of the Buy range.
The strongest dimensions tell a growth-and-execution story. CAH is rated Excellent on the Growth Index, a rating backed by 5.84% revenue growth and quarterly revenue that rose from $60.94 billion in Q1 2026 to $63.67 billion in Q2 2026. Fiscal Q1 2027 then pushed it further to $67.51 billion. For a company already moving more than $60 billion a quarter, that steady compounding is significant.
The Excellent rating on the Efficiency Index stands out despite a 0.67% profit margin. Drug distribution runs on razor-thin spreads, so Cardinal wins by pushing enormous volume through its network at low cost. The 17% segment profit increase on 6% revenue growth shows that model working. The Excellent Total Return Index reflects a stock that has gained roughly 55% off its 52-week low and keeps setting new highs. The Good rating on the Volatility Index shows those gains have come without the wild swings typical of momentum names. Even today's sharp move rests on a fundamental catalyst, the earnings beat and guidance raise, rather than speculative churn.
Where the picture becomes more nuanced is the balance sheet and the payout. CAH is rated Fair on the Solvency Index, which reflects the working-capital demands and leverage that come with running a distribution operation of this scale. That rating is a key reason the overall grade sits at B+ rather than higher. The Dividend Index is also rated Fair. A 0.81% yield is modest, and the stock's sharp appreciation has compressed it further, so income-focused investors will find more appeal in the total return profile than in the payout itself.
Within the Health Care sector, Cardinal Health ranks ahead of McKesson Corporation (MCK, B) and Cencora, Inc. (COR, B), its two closest distribution rivals. It also sits above Medtronic plc (MDT, B-) and HCA Healthcare, Inc. (HCA, B-). Only Labcorp Holdings Inc. (LH, A-) carries a stronger rating among this peer set, which leaves Cardinal as the top-rated name among the major drug distributors.
About Cardinal Health, Inc.
Cardinal Health, Inc. (CAH) is a Health Care company operating within the Health Care Equipment and Services industry. Incorporated in 1979 and headquartered in Dublin, Ohio, it serves hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home across the United States and internationally. The business runs through two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.
The pharmaceutical side distributes branded, generic, specialty, and over-the-counter products, and it generates the vast majority of revenue. It also provides specialty pharmaceutical services to manufacturers and providers, offers pharmacy management services to hospitals, operates pharmacies including those in community health centers, and repackages generic drugs and over-the-counter products. Cardinal also manufactures, prepares, and delivers radiopharmaceuticals, a specialized niche with high barriers to entry.
The Global Medical Products and Distribution segment manufactures and sources Cardinal Health branded products. These include exam and surgical gloves, needles, syringes and sharps disposals, wound care, compression, incontinence and nutritional delivery products, surgical drapes and gowns, fluid suction systems, urology products, and electrode lines. The segment also distributes national brand medical, surgical, and laboratory products and assembles sterile and non-sterile procedure kits. Cardinal's competitive edge comes from its scale, its entrenched relationships across the care continuum, and integrated technology that optimizes direct shipments, all of which are difficult for smaller rivals to replicate.
Investor Outlook
Cardinal Health, Inc. (CAH) carries a Weiss Rating of B+ (Buy), and a beat-and-raise quarter has pushed the stock to fresh highs on solid fundamental footing. Investors should watch whether Pharmaceutical and Specialty Solutions profit growth holds within the newly raised 10%–12% range and whether the company keeps tracking toward its $12.80–$13.00 adjusted EPS target. See full rankings of all B+ rated Health Care stocks inside the Weiss Stock Screener.
--